X4 Pharmaceuticals (XFOR) EBIT Margin (2018 - 2025)
X4 Pharmaceuticals (XFOR) reported EBIT Margin of 922.86% for Q4 2025, up 156773.0% on a YoY basis from N/an in Q4 2024, and up 40.79% quarter-over-quarter from 1558.58% in Q3 2025.
X4 Pharmaceuticals (XFOR) EBIT Margin (2018 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported EBIT Margin for 4 years, with the latest figure at 922.86% in Q4 2025.
- For the quarter ending Q4 2025, EBIT Margin rose 156773.0% year-over-year to 922.86%; the trailing twelve-month figure through Dec 2025 stood at 247.44% (up 117614.0% YoY), and the FY2025 full-year result was 247.44%, up 117614.0% from the prior year.
- EBIT Margin for Q4 2025 stood at 922.86%, up from 1558.58% in the prior quarter.
- The five-year high for EBIT Margin was 12629.31% in Q2 2024, with the low at 6160.71% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | X4 Pharmaceuticals | 156.06 Mn | 156.06 Mn | 2.20 Mn | -922.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -922.86% |
| Sep 30, 2025 | -1,558.58% |
| Jun 30, 2025 | -1,329.55% |
| Mar 31, 2025 | -32.78% |
| Dec 31, 2024 | -2,490.59% |
| Sep 30, 2024 | -6,160.71% |
| Jun 30, 2024 | 12,629.31% |
| Mar 31, 2020 | -352.70% |
| Dec 31, 2018 | -230.11% |